UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 375

Sortiert nach

Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis

Thrombosis and haemostasis, 2001-03, Vol.85 (3), p.560

2001

Volltextzugriff (PDF)

Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity

Journal of thrombosis and haemostasis, 2004-10, Vol.2 (10), p.1700-1708

Aledort, L. M.

2004

Volltextzugriff (PDF)

The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-09, Vol.22 (5), p.676-683

Aledort, L. M.

2016

Volltextzugriff (PDF)

Idiopathic thrombocytopenic purpura : A practice guideline developed by explicit methods for the American Society of Hematology

Blood, 1996-07, Vol.88 (1), p.3-40

1996

Volltextzugriff (PDF)

Is the incidence and prevalence of inhibitors greater with recombinant products? Yes

Journal of thrombosis and haemostasis, 2004-06, Vol.2 (6), p.861-862

Aledort, L. M.

2004

Volltextzugriff (PDF)

Can B‐domain deletion alter the immunogenicity of recombinant factor VIII? A meta‐analysis of prospective clinical studies

Journal of thrombosis and haemostasis, 2011-11, Vol.9 (11), p.2180-2192

2011

Volltextzugriff (PDF)

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors

Thrombosis and haemostasis, 1998-12, Vol.80 (6), p.912

1998

Volltextzugriff (PDF)

Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues

Haemophilia : the official journal of the World Federation of Hemophilia, 2008-01, Vol.14 (1), p.39-43

ALEDORT, L. M.

2008

Volltextzugriff (PDF)

Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment

Journal of thrombosis and haemostasis, 2011-03, Vol.9 (3), p.423-427

ALEDORT, L. M.

2011

Volltextzugriff (PDF)

The effect of a specialized case management programme on the cost of factor replacement use in patients with bleeding disorders

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-05, Vol.20 (3), p.e240-e242

Aledort, L. M.

2014

Volltextzugriff (PDF)

Evaluation of bleeding and thrombotic events during long‐term use of romiplostim in patients with chronic immune thrombocytopenia (ITP)

Journal of thrombosis and haemostasis, 2010-06, Vol.8 (6), p.1372-1382

2010

Volltextzugriff (PDF)

Intravenous anti-D treatment of immune thrombocytopenic purpura: Experience in 272 patients

Blood, 1997-04, Vol.89 (8), p.2689-2700

1997

Volltextzugriff (PDF)

rFVIIa--its thrombogenicity

Thrombosis and haemostasis, 2000-09, Vol.84 (3), p.522

Aledort, L M

2000

Volltextzugriff (PDF)

Can we prevent inhibitors in mild and moderate factor VIII‐deficient patients?

Journal of thrombosis and haemostasis, 2006-04, Vol.4 (4), p.914-914

ALEDORT, L. M.

2006

Volltextzugriff (PDF)

A Prospective Study of Treatment of Acquired (Autoimmune) Factor VIII Inhibitors With High-Dose Intravenous Gammaglobulin

Blood, 1995-07, Vol.86 (2), p.797-804

1995

Volltextzugriff (PDF)

Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-01, Vol.20 (1), p.83-91

2014

Volltextzugriff (PDF)

Disseminated Intravascular Coagulation Complicating Epstein-Barr Virus Infection in a Cardiac Transplant Recipient: A Case Report

Transplantation proceedings, 2010-06, Vol.42 (5), p.1973-1975

2010

Volltextzugriff (PDF)

Another role for the VW molecule

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-03, Vol.18 (2), p.246-247

ALEDORT, L. M.

2012

Volltextzugriff (PDF)

The EPIC study: a lesson to learn

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-09, Vol.21 (5), p.622-628

2015

Volltextzugriff (PDF)

Best evidence on B‐domain deletion and the immunogenicity of recombinant factor VIII

Journal of thrombosis and haemostasis, 2011-11, Vol.9 (11), p.2325-2327

2011

Volltextzugriff (PDF)

To bleed or not to bleed – is that a question?

Journal of thrombosis and haemostasis, 2010-01, Vol.8 (1), p.81-82

ALEDORT, L. M.

2010

Volltextzugriff (PDF)

Optimizing the treatment of haemophilia B: laboratory and clinical perspectives

Haemophilia : the official journal of the World Federation of Hemophilia, 2010-07, Vol.16 (s6), p.1-2

ALEDORT, L. M.

2010

Volltextzugriff (PDF)

Prophylactic use of factor VIII: an economic evaluation

Thrombosis and haemostasis, 1998-05, Vol.79 (5), p.932

1998

Volltextzugriff (PDF)

Mild and moderate factor VIII deficiency: inhibitor risks

Journal of thrombosis and haemostasis, 2009-06, Vol.7 (6), p.928-929

ALEDORT, L. M.

2009

Volltextzugriff (PDF)

Inhibitors occur more frequently in African–American and Latino Haemophiliacs

Haemophilia : the official journal of the World Federation of Hemophilia, 1998-01, Vol.4 (1), p.68-68

1998

Volltextzugriff (PDF)

1 – 25 von 375

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(346)
Mit Volltextzugriff
(247)

Publikationsform

Sprache

Englisch
(375)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Humans
(255)
Science & Technology
(220)
Life Sciences & Biomedicine
(217)
Hematology
(146)
Adult
(88)
Biological And Medical Sciences
(83)
Male
(82)
Medical Sciences
(81)
Hemophilia A - Complications
(54)
Hemophilia A - Therapy
(54)
Child
(53)
Adolescent
(51)
Middle Aged
(51)
Factor Viii - Therapeutic Use
(50)
Female
(50)
Hemophilia A - Drug Therapy
(47)
Aids/hiv
(43)
Hematologic And Hematopoietic Diseases
(40)
Cardiovascular System & Cardiology
(39)
Hemophilia A - Immunology
(36)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis

Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity

The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline

Idiopathic thrombocytopenic purpura : A practice guideline developed by explicit methods for the American Society of Hematology

Is the incidence and prevalence of inhibitors greater with recombinant products? Yes

Can B‐domain deletion alter the immunogenicity of recombinant factor VIII? A meta‐analysis of prospective clinical studies

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors

Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues

Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment

The effect of a specialized case management programme on the cost of factor replacement use in patients with bleeding disorders

Evaluation of bleeding and thrombotic events during long‐term use of romiplostim in patients with chronic immune thrombocytopenia (ITP)

Intravenous anti-D treatment of immune thrombocytopenic purpura: Experience in 272 patients

rFVIIa--its thrombogenicity

Can we prevent inhibitors in mild and moderate factor VIII‐deficient patients?

A Prospective Study of Treatment of Acquired (Autoimmune) Factor VIII Inhibitors With High-Dose Intravenous Gammaglobulin

Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate

Disseminated Intravascular Coagulation Complicating Epstein-Barr Virus Infection in a Cardiac Transplant Recipient: A Case Report

Another role for the VW molecule

The EPIC study: a lesson to learn

Best evidence on B‐domain deletion and the immunogenicity of recombinant factor VIII

To bleed or not to bleed – is that a question?

Optimizing the treatment of haemophilia B: laboratory and clinical perspectives

Prophylactic use of factor VIII: an economic evaluation

Mild and moderate factor VIII deficiency: inhibitor risks

Inhibitors occur more frequently in African–American and Latino Haemophiliacs

Suchergebnisse filtern